Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 4
2011 5
2012 5
2013 12
2014 14
2015 13
2016 18
2017 11
2018 15
2019 18
2020 15
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 31982351

115 results
Results by year
Filters applied: . Clear all
Page 1
High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases.
Brunsell TH, Sveen A, Bjørnbeth BA, Røsok BI, Danielsen SA, Brudvik KW, Berg KCG, Johannessen B, Cengija V, Abildgaard A, Guren MG, Nesbakken A, Lothe RA. Brunsell TH, et al. Clin Colorectal Cancer. 2020 Mar;19(1):e26-e47. doi: 10.1016/j.clcc.2019.09.003. Epub 2019 Dec 12. Clin Colorectal Cancer. 2020. PMID: 31982351 Free article.
Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.
Normanno N, Rachiglio AM, Lambiase M, Martinelli E, Fenizia F, Esposito C, Roma C, Troiani T, Rizzi D, Tatangelo F, Botti G, Maiello E, Colucci G, Ciardiello F; CAPRI-GOIM investigators. Normanno N, et al. Ann Oncol. 2015 Aug;26(8):1710-4. doi: 10.1093/annonc/mdv176. Epub 2015 Apr 7. Ann Oncol. 2015. PMID: 25851630 Free article. Clinical Trial.
Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients.
Sclafani F, Wilson SH, Cunningham D, Gonzalez De Castro D, Kalaitzaki E, Begum R, Wotherspoon A, Capdevila J, Glimelius B, Roselló S, Thomas J, Tait D, Brown G, Oates J, Chau I. Sclafani F, et al. Int J Cancer. 2020 Jan 1;146(1):94-102. doi: 10.1002/ijc.32507. Epub 2019 Jul 5. Int J Cancer. 2020. PMID: 31199501 Clinical Trial.
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S. De Roock W, et al. Lancet Oncol. 2010 Aug;11(8):753-62. doi: 10.1016/S1470-2045(10)70130-3. Epub 2010 Jul 8. Lancet Oncol. 2010. PMID: 20619739 Clinical Trial.
Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
Nakayama I, Shinozaki E, Matsushima T, Wakatsuki T, Ogura M, Ichimura T, Ozaka M, Takahari D, Suenaga M, Chin K, Mizunuma N, Yamaguchi K. Nakayama I, et al. BMC Cancer. 2017 Jan 9;17(1):38. doi: 10.1186/s12885-016-2994-6. BMC Cancer. 2017. PMID: 28068936 Free PMC article.
Elucidating the prognostic significance of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese patients with metastatic colorectal cancer.
Ma BB, Mo F, Tong JH, Wong A, Wong SC, Ho WM, Wu C, Lam PW, Chan KF, Chan TS, Tsui WM, Tsang AK, Fung MN, Chan AT, To KF. Ma BB, et al. Asia Pac J Clin Oncol. 2015 Jun;11(2):160-9. doi: 10.1111/ajco.12342. Epub 2015 Apr 13. Asia Pac J Clin Oncol. 2015. PMID: 25865669
115 results
Jump to page
Feedback